Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … The acquisition has been approved by the boards of both companies, and is expected to close in the second quarter. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. SIRTRIS PHARMA INC. Weekly Stock Prices Chart. And Sirtris says it is close to launching clinical trials for experimental drugs that could prove to be up to 1,000 times more potent. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Their stock opened with $10.00 in its May 23, 2007 IPO. The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. $376M. The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. Description. Company profile page for Sirtris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information via: Sirtris Markets Data Center: Biggest Price Gainers. Latest Deal Amount. Markets Data Center: Biggest Price Gainers. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. Action Alerts PLUS is a registered trademark of TheStreet, Inc. As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. © 2021 TheStreet, Inc. All rights reserved. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. //-->. [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. M&A. Stock Symbol NASDAQ:SIRT ; Money Raised at IPO $60M; IPO Share Price $10.00; IPO Date May 23, 2007; Delisted Date Mar 13, 2013